By Sherri Oslick —

About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

AstraZeneca
AB et al. v. Watson Laboratories, Inc. – Florida et al.
3:13-cv-01669;
filed March 19, 2013 in the District Court of New Jersey

• Plaintiffs: 
AstraZeneca AB; Aktiebolaget Hassle; AstraZeneca LP; KBI Inc.; KBI-E Inc.
• Defendants: 
Watson Laboratories, Inc. – Florida; Watson Pharma, Inc.; Actavis, Inc.

Infringement
of U.S. Patent Nos. 5,714,504 ("Compositions," issued February 3,
1988), 5,877,192 ("Method for the Treatment of Gastric Acid-Related
Diseases and Production of Medication Using (-)Enantiomer of Omeprazole,"
issued March 2, 1999), 6,369,085 ("Form of S-omeprazole," issued
April 9, 2002), 6,875,872 ("Compounds," issued April 5, 2005), and
7,411,070 (same title, issued August 12, 2008) following a Paragraph IV
certification as part of defendants' filing of an ANDA to manufacture a generic
version of AstraZeneca's Nexium® (esomeprazole magnesium, used for the
treatment of gastroesophageal reflux disease). 
View the complaint here.

Pharmacia
& Upjohn Co. LLC et al. v. Apotex, Inc. et al.
1:13-cv-02034;
filed March 15, 2013 in the Northern District of Illinois

• Plaintiffs: 
Pharmacia & Upjohn Co. LLC; Pfizer Asia-Pacific Pte. Ltd.
• Defendants: 
Apotex, Inc.; Apotex, Corp.

Infringement
of U.S. Patent No. 5,688,792 ("Substituted Oxazine and Thiazine
Oxazolidinone Antimicrobials," issued November 18, 1997) following a
Paragraph IV certification as part of Aptoex's filing of an ANDA to manufacture
a generic version of Pfizer's Zyvox® (linezolid, used to treat bacterial infections).  View the complaint here.

Intendis GmbH
et al. v. Glenmark Generics Ltd. et al.
1:13-cv-00421;
filed March 14, 2013 in the District Court of Delaware

• Plaintiffs: 
Intendis GmbH; Intraserv GmbH & Co. KG; Bayer HealthCare Pharmaceuticals
Inc.
• Defendants: 
Glenmark Generics Ltd.; Glenmark Generics Inc. USA

Infringement
of U.S. Patent No. 6,534,070 ("Composition with Azelaic Acid," issued
March 18, 2003) following a Paragraph IV certification as part of Glenmark's
filing of an ANDA to manufacture a generic version of Bayer's Finacea® (azelaic
acid gel, used for the topical treatment of inflammatory papules and pustules
of mild to moderate rosacea).  View the
complaint here.

Boehringer
Ingelheim Pharma GmbH & Co. KG et al. v. Kremers Urban Pharmaceuticals,
Inc.
1:13-cv-01580;
filed March 14, 2013 in the District Court of New Jersey

• Plaintiffs: 
Boehringer Ingelheim Pharma GmbH & Co. KG; Boehringer Ingelheim
International GmbH; Boehringer Ingelheim Pharmaceuticals, Inc.
• Defendant: 
Kremers Urban Pharmaceuticals, Inc.

Infringement
of U.S. Patent No. 6,015,577 ("Pharmaceutical Compositions Containing
Dipyridamole or Mopidamol and Acetylsalicylic Acid or the Physiologically
Acceptable Salts Thereof, Processes for Preparing Them and Their Use in
Treating Clot Formation," issued January 18, 2000) following a Paragraph
IV certification as part of Kremers' filing of an ANDA to manufacture a generic
version of Boehringer's Aggrenox® (extended-release dipyridamole/acetylsalicylic
acid, used to reduce the risk of stroke in patients who have had transient
ischemia of the brain or completed ischemic stroke due to thrombosis).  View the complaint here.